[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"heart-failure-acute\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:heart-failure-acute":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,56,83,113,141,168,199,229,252,280,311,332,357,382],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":37,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100605188","cardiac-point-of-care-ultrasound-training-pathway-for-emergency-department-advanced-practice-providers-100605188",false,"NCT07159269","Cardiac point-of Care Ultrasound Training Pathway for Emergency Department Advanced Practice Providers","Cardiac Point-of-care Ultrasound Clinical Training Pathway Implementation and Impact Assessment for Advanced Practice Providers in the Emergency Department","Inclusion Criteria:\n\n* advanced practice providers (APPs) currently working in our ED, with additional APPs as they are hired (expected to be about 75 APPs total within the next 3 years due to expanding staffing needs and coverage models).\n\nExclusion Criteria:\n\n* non-APPs such as physicians, nurses, or other clinical staff",true,"ALL","18 Years",{"count":20,"type":21},75,"ESTIMATED","INTERVENTIONAL",[24],"NA","The aim of this study is to assess emergency medicine physician and advanced practice provider (APP) knowledge and technical skill in performance of a point-of-care ultrasound simulation and just-in-time training pathway to determine the feasibility, acceptability, and usability of the ultrasound training program. By performing this study, we hope to create a standardized training model which could potentially facilitate point-of-care ultrasound (POCUS) clinical performance and thereby improve patient care.",[27,28,29,30,31,32,33,34,35,36],"Cardiovascular Disease Acute","Emergency Department Patient","Heart Failure Acute","Pulmonary Embolism (Diagnosis)","Point of Care Ultrasound (POCUS)","Cardiac Tamponade","Pericardial Effusion","Diagnostic Imaging","Medical Training","Implementation Science",[38,39,40,41,42],"point of care ultrasound","focused cardiac ultrasound","advanced practice provider training","medical education","implementation science","RECRUITING","2026-06-01",{"date":46,"type":47},"2026-06-03","ACTUAL",{"date":49,"type":47},"2025-11-13",{"date":51,"type":21},"2030-06-30",{"name":53,"class":54},"Duke University","OTHER",1,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":22,"phases":65,"briefSummary":66,"conditions":67,"keywords":70,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":4},"100640993","simulation-based-cardiac-point-of-care-ultrasound-program-to-improve-clinical-outcomes-in-acute-heart-failure-patients-100640993","NCT07592598","Simulation-Based Cardiac Point-of-Care Ultrasound Program to Improve Clinical Outcomes in Acute Heart Failure Patients","Co-design and Implementation of a Simulation-Based Cardiac Point-of-Care Ultrasound Program to Improve Clinical Outcomes in Acute Heart Failure Patients","Inclusion Criteria:\n\n* Emergency medicine provider practicing at the study site, including physician assistants and nurse practitioners\n\nExclusion Criteria:\n\n* ED nurses and technicians are excluded due to differing ultrasound training needs",{"count":64,"type":21},175,[24],"The aim of this study is to co-design a cardiac POCUS simulation training intervention and implementation strategy for EM clinicians and evaluate the effectiveness of the cardiac point-of-care ultrasound (POCUS) simulation-based training (CPST) and CPG implementation. By performing this study, the investigators hope to improve diagnostic processes and time-to-diuretic dosing for acute heart failure (AHF) patients.",[29,68,69,36],"Point-of-care Ultrasound","Simulation Training",[71,72,73,42],"acute heart failure","point-of-care ultrasound","simulation training","NOT_YET_RECRUITING","2026-05-11",{"date":77,"type":47},"2026-05-18",{"date":79,"type":21},"2026-09-01",{"date":81,"type":21},"2030-12-31",{"name":53,"class":54},{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":22,"phases":92,"briefSummary":93,"conditions":94,"keywords":98,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":112},"100635908","vexus-assessment-and-natriuresis-guided-diuretic-therapy-in-acute-heart-failure-100635908","NCT07558798","Vexus Assessment and Natriuresis-guided Diuretic Therapy in Acute Heart Failure","VANTAGE-HF","Inclusion Criteria:\n\n* Age \\>18 years\n* Hospitalization with AHF, either de novo or worsening of chronic HF\n* Able to provide written informed consent\n* Requirement of intravenous loop diuretic treatment as judged by the treating physician\n\nExclusion Criteria:\n\n* Dyspnea primarily due to non-cardiac causes\n* Advanced renal disease or estimated glomerular filtration rate (eGFR) \\\u003C 20 mL\u002Fmin\u002F1.73m2 at screening or on-going dialysis.\n* Enrollment in another study interfering with the treatment algorithm of the current study\n* Inability to follow the treatment protocol\n* Language barriers requiring the need for an external interpreter\n* Pregnant or nursing (lactating) women\n* Very short life expectancy (\\\u003C30 days)",{"count":91,"type":21},270,[24],"This study evaluates whether natriuresis-guided diuretic therapy improves outcomes in patients with acute heart failure (AHF) and severe congestion. All patients hospitalized with AHF will be screened using Venous Excess Ultrasound (VExUS) and randomized 1:1 to either natriuresis-guided escalation of loop diuretics or standard care. The primary endpoint, evaluated in patients with VExUS grade 3 (severe congestion), is a hierarchical composite (win ratio) of 90-day mortality, 90-day rehospitalization, and hospital length of stay. Key secondary endpoints (hierarchical) include (1) difference in win ratio between patients with VExUS 3 versus VExUS 0-2 at hospital admission (assessed by interaction testing and statistically tested only if the primary endpoint is significant) and (2) win ratio (primary endpoint) tested among patients with VExUS 0-2 at hospital admission (statistically tested only if the first key seconday endpoint is significant). Exploratory endpoints include in-hospital clinical, hemodynamic, and biochemical outcomes (mortality, eGFR, NT-proBNP, NYHA class, VExUS score, natriuresis\u002Fdiuresis, and patient-reported dyspnea), associations between congestion markers (VExUS, FibroScan, lung ultrasound, clinical score, and NT-proBNP), as well as quality of life at 90 days, GDMT optimization score at discharge, and long-term time to readmission and mortality assessed through registry linkage.",[95,29,96,97],"Venous Congestion","VExUS","Diuretics",[99,100,71,101,102],"loop diuretics","heart failure","vexus","congestion","2026-04-23",{"date":105,"type":47},"2026-04-30",{"date":107,"type":21},"2026-04",{"date":109,"type":21},"2028-06",{"name":111,"class":54},"University Hospital, Akershus",2,{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":17,"minAge":121,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":22,"phases":124,"briefSummary":125,"conditions":126,"keywords":128,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":55},"100635292","contrast-induced-acute-kidney-injury-prevention-in-acute-heart-failure-100635292","NCT07550790","Contrast-Induced Acute Kidney Injury Prevention in Acute Heart Failure","Contrast-Induced Acute Kidney Injury in Acute Heart Failure With Renal Dysfunction: The Kidney Protection Strategies Evaluation in Acute Heart Failure (K-PROSE)","K-PROSE","Inclusion Criteria:\n\n* Adults aged 20 years or older\n* Emergency department visit\u002Fhospitalization for acute heart failure with clinical evidence of congestion\n* Planned contrast-enhanced computed tomography during the index hospitalization\n* Baseline renal dysfunction defined as an estimated glomerular filtration rate (eGFR) of 30-75 mL\u002Fmin\u002F1.73 m²\n\nExclusion Criteria:\n\n* Requirement for vasopressor therapy\n* Requirement for renal replacement therapy (dialysis)\n* Known allergy or hypersensitivity to furosemide\n* Ongoing acute coronary syndrome\n* Pregnant or breastfeeding women, or women of childbearing potential without a negative pregnancy test\n* Hyperkalemia (serum potassium \\>5.5 mmol\u002FL)\n* Uncorrected volume depletion or hyponatremia (serum sodium \\\u003C130 mmol\u002FL)\n* Any condition deemed by the investigator to make participation in the study inappropriate","20 Years",{"count":123,"type":21},190,[24],"The K-PROSE study is a randomized clinical investigation evaluating strategies to prevent contrast-induced acute kidney injury (CI-AKI) in patients hospitalized with acute heart failure and moderate renal dysfunction (eGFR 30-75 mL\u002Fmin\u002F1.73 m²). Patients requiring contrast-enhanced CT imaging are randomized to either standard intravenous saline hydration or a furosemide-based decongestion strategy. Renal function is assessed using serial measurements of creatinine and cystatin C, before and after contrast exposure. By comparing renal outcomes, congestion status, and safety profiles, this study aims to determine whether a decongestion-focused approach provides superior renal protection compared with conventional hydration in high-risk acute heart failure patients.",[29,127],"Renal Dysfunction",[129,130,131],"contrast-induced acute kidney injury","decongestion","hydration","2026-04-19",{"date":134,"type":47},"2026-04-24",{"date":136,"type":21},"2026-05-01",{"date":138,"type":21},"2029-01-30",{"name":140,"class":54},"Seoul National University Bundang Hospital",{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":22,"phases":151,"briefSummary":152,"conditions":153,"keywords":154,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":112},"100523193","investigating-a-tailored-diuretic-algorithm-in-acute-heart-failure-patients-100523193","NCT06092437","Investigating a Tailored Diuretic Algorithm in Acute Heart Failure Patients","TAILOR-AHF: Randomized Trial Investigating a Tailored Diuretic Algorithm in Acute Heart Failure Patients","TAILOR-AHF","Inclusion Criteria:\n\n* Age \\> 18 years;\n* HF (HFrEF, HFmrEF or HFpEF) diagnosed according to the 2021 HF Guidelines of the European Society of Cardiology \\[5\\];\n* Presentation with AHF meaning at least one symptom (dyspnea, orthopnea, or edema) and one sign (rales, peripheral edema, ascites, or pulmonary vascular congestion on chest radiography) of AHF;\n* An elevated NT-proBNP \\>300pg\u002Fml;\n* Requiring the need for iv diuretics.\n\nExclusion Criteria:\n\n* Terminal renal insufficiency defined as: dialysis patients or eGFR (estimated glomerular filtration rate) \\\u003C 10 mL\u002Fmin\u002F1.73 m2;\n* Patients included in other investigational studies regarding heart failure.\n* Presentation with cardiogenic shock or respiratory insufficiency or another reason requiring admission to the intensive care unit upon admission (IC transfer later in the hospitalization is not an exclusion).",{"count":150,"type":21},556,[24],"Acutely decompensated heart failure (ADHF) is highly prevalent and has a high (financial) burden on the health care system. Treatment often consists of the administration of IV decongestive agents. Adequate dosing is difficult due to varying diuretic resistance and inadequate parameters to evaluate the response. Urine sodium is a promising biomarker to evaluate the diuretic response. It is hypothesized that a tailored, urine sodium guided diuretic algorithm will result in faster and more complete decongestion and therefore lead to better survival (in terms of mortality and heart failure events) while being non-inferior in terms of safety (mainly regression of kidney function).",[29],[155,156,157,158],"Decongestion","Heart failure","Natriuresis","Urinary Sodium","2026-04-07",{"date":161,"type":47},"2026-04-13",{"date":163,"type":47},"2023-02-27",{"date":165,"type":21},"2026-08-27",{"name":167,"class":54},"Zuyderland Medisch Centrum",{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":172,"acronym":173,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":175,"targetDuration":4,"studyType":22,"phases":177,"briefSummary":179,"conditions":180,"keywords":184,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":55},"100613165","phase-4-urine-sodium-driven-diuretic-adjustment-strategy-in-acute-decompensated-heart-failure-100613165","NCT07263035","Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure","US-DASH","Inclusion Criteria:\n\n* The study will target adults 18 years of age or older admitted to Lakeland Regional Medical Center who:\n\n  * Have a primary diagnosis of acute decompensated heart failure, and\n  * Have at least one of the following signs of hypervolemia:\n\n    * Bilateral lower extremity pitting edema\n    * Jugular venous distension\n    * Hepatojugular reflex\n    * Crackles on pulmonary exam, or\n    * Chest x-ray demonstrating pulmonary edema or pleural effusions\n\nExclusion Criteria:\n\n* Exclusion criteria include:\n\n  * Admission to the intensive care unit\n  * Presence of ST-elevated myocardial infarction\n  * Presence of type 1 non-ST elevated myocardial infarction\n  * Dyspnea primarily due to non-cardiac cause as judged by the emergency medicine physician or admitting physician\n  * Use of supplemental oxygen totaling at least 3 L per minute or greater at baseline\n  * Anuria\n  * End-stage renal disease per KDIGO criteria\n  * Dialysis use",{"count":176,"type":21},600,[178],"PHASE4","The goal of this clinical trial is to learn if increasing the dose of diuretics to achieve a higher urine sodium target produces better clinical results when treating patients hospitalized with acute heart failure when compared to lower urine sodium target and standard of care.\n\nThe main questions it aims to answer are:\n\n1. Does targeting a higher urine sodium goal achieve greater natriuresis and diuresis?\n2. Does targeting a higher urine sodium goal reduce frequency of hospital readmissions?\n3. Does targeting a higher urine sodium goal reduce hospital length of stay?\n\nResearchers will compare natriuresis-guided arms with standard of care to see if targeting higher natriuresis goals improves significantly over current practice.\n\nParticipants will submit urine samples at routine intervals after being given diuretics to evaluate urine sodium concentration. If urine sodium is low then diuretic dose will be increased.",[181,182,29,183],"Heart Failure","Heart Failure - NYHA II - IV","Acute Heart Failure (AHF)",[185,97,186,100,187,188,189,157],"Urine sodium","Lasix","Acute CHF","acute HFrEF","Acute HFpEF","2026-04-06",{"date":192,"type":47},"2026-04-09",{"date":194,"type":47},"2026-04-01",{"date":196,"type":21},"2027-09-01",{"name":198,"class":54},"Lakeland Regional Health Systems, Inc.",{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":207,"targetDuration":4,"studyType":209,"phases":4,"briefSummary":210,"conditions":211,"keywords":214,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":55},"100619479","congestion-and-lactate-at-discharge-in-acute-heart-failure-100619479","NCT07345156","Congestion and LActate at diScHarge in Acute Heart Failure","Validation of a Combined Score Combining the Lung Ultrasound Score and Lactate at Discharge for Predicting Early Events After Acute Heart Failure","CLASH-HF","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Hospitalization for acute heart failure\u002Fdecompensation (clinical diagnosis + imaging\u002Flaboratory tests according to local practice).\n* Patient deemed ready for discharge (decision made by the team, discharge within 24 hours).\n\nExclusion Criteria:\n\n* Septic shock\u002Fsevere active infection at the time of discharge.\n* Hypoxemia or respiratory distress requiring high-flow oxygen\u002Fventilation at the scheduled time of discharge.\n* Severe cirrhosis\u002Fadvanced liver failure.\n* Refusal to participate.\n* Technical impossibility of LUS.",{"count":208,"type":21},350,"OBSERVATIONAL","Acute heart failure (AHF) is a leading cause of hospitalization and is associated with high short-term morbidity and mortality, with 20-30% of patients experiencing rehospitalization or death within 30 days. Early adverse events often reflect incomplete recovery, highlighting the need for improved risk stratification after clinical stabilization .Current prognostic approaches mainly focus on hemodynamic congestion. Persistent pulmonary congestion at discharge is a strong predictor of poor outcomes, but these markers primarily assess macrocirculatory abnormalities and do not capture microcirculatory dysfunction, which may persist despite apparent clinical improvement. Lung ultrasound, through the Lung Ultrasound Score (LUS), provides a validated assessment of pulmonary congestion and has demonstrated prognostic value in AHF. However, LUS does not reflect systemic tissue perfusion. In contrast, blood lactate is a robust marker of tissue hypoperfusion, and even mild elevations have been associated with worse outcomes in AHF. A combined score integrating LUS and lactate may therefore better reflect the dual pathophysiology of AHF-persistent congestion and impaired tissue perfusion-and improve prediction of early adverse events.\n\nThis protocol aims to validate the prognostic value of this combined score for predicting 30-day rehospitalization or death in patients hospitalized for AHF, with the hypothesis that it outperforms LUS alone.",[29,212,213],"Discharge Follow-up Phone Calls","Mortality Prediction",[215,216,217,218,219],"Lung Ultrasound Score","Lactate","Combined score","Acute Heart Failure","Discharge","2026-01-08",{"date":222,"type":47},"2026-01-15",{"date":224,"type":21},"2026-01-01",{"date":226,"type":21},"2026-12-30",{"name":228,"class":54},"University of Monastir",{"id":230,"slug":231,"hasResults":11,"nctId":232,"briefTitle":233,"officialTitle":233,"acronym":234,"eligibilityCriteria":235,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":236,"targetDuration":4,"studyType":209,"phases":4,"briefSummary":238,"conditions":239,"keywords":241,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":4},"100604298","evaluation-of-the-effectiveness-of-the-cardiostory-device-in-distinguishing-heart-failure-from-other-causes-in-patients-presenting-with-dyspnea-100604298","NCT07147699","Evaluation of the Effectiveness of the CardioStory Device in Distinguishing Heart Failure From Other Causes in Patients Presenting With Dyspnea","CARDIOSTORY","Inclusion Criteria:\n\n* • Age ≥ 18 years\n\n  * Recent onset dyspnea (less than 7 days)\n  * Informed consent obtained\n\nExclusion Criteria:\n\n* • Age inferior to 18 years,\n\n  * Severe comorbidity, hemodynamic compromise or immediate need for mechanical ventilation were exclusion criteria.\n  * Dyspnea clearly of traumatic or allergic origin",{"count":237,"type":21},650,"The CARDIOSTORY.TN study is a prospective observational study at Sahloul University Hospital (Sousse, Tunisia) evaluating the CardioStory device for distinguishing heart failure (HF) from other causes of acute dyspnea.\n\nBackground: Dyspnea is common in emergencies, and differentiating cardiac from non-cardiac causes is often delayed by the limits of echocardiography and BNP tests. CardioStory is a rapid (\\~2 minutes), non-invasive tool that measures cardiac filling pressure, a key HF marker.\n\nObjectives:\n\nPrimary: Assess CardioStory's diagnostic accuracy.\n\nSecondary: Compare it with echocardiography and NT-proBNP, evaluate ease of use, and measure time to diagnosis.\n\nMethods:\n\nAdults (≥18) with acute dyspnea (\\\u003C7 days) included; unstable or traumatic\u002Fallergic cases excluded.\n\nCardioStory results will be compared to standard diagnostics.\n\nSample size: 850 patients over 12 months.\n\nOutcome: If accurate, CardioStory could be a fast, practical diagnostic tool for emergency settings.",[240,29],"Dyspnea",[242,71],"dyspnea","2025-08-28",{"date":245,"type":47},"2025-08-29",{"date":247,"type":21},"2025-09-01",{"date":249,"type":21},"2026-12-01",{"name":251,"class":54},"Hôpital Universitaire Sahloul",{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":258,"eligibilityCriteria":259,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":260,"targetDuration":4,"studyType":209,"phases":4,"briefSummary":262,"conditions":263,"keywords":267,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":55},"100579078","prediction-of-heart-failure-with-machine-learning-100579078","NCT06819618","Prediction of Heart-Failure with Machine Learning","Predicting Heart Failure Recovery by Wearables and Machine Learning","PRE-HF-ML","Inclusion Criteria:\n\n* age over 17\n* HFrEF with LV-EF under 41\n* hospitalized for decompensated heart failure with a) nTproBNP over 1000 AND b) willing to participate AND c) at least one out of three clinical signs (edema, pleural effusion, ascites)\n\nExclusion Criteria:\n\n* life expectancy under 6 months due to non-cardiac conditions\n* inability to use smartwatch\n* severe valvular lesions",{"count":261,"type":21},32,"In this monocentric observational study the research question is to what extent data collected via Apple Watch can predict the heart failure status of decompensated HF patients. For this purpose, physiological data from the Apple Watch (such as single-lead electrocardiogram, SpO2, respiratory rate, step count, nighttime temperature, etc.) will be extracted and used as predictor variables to forecast outcomes like risk of decompensation and rehospitalization within the follow-up period. Since this is a data-driven study, additional data collected as part of guideline-compliant treatment will also be included.",[264,181,265,29,266],"Heart Failure with Reduced Ejection Fraction","Heart Failure，Congestive","Heart Failure; with Decompensation",[181,268,269,270],"Wearables","Monitoring","Apple Watch","2025-02-09",{"date":273,"type":47},"2025-02-11",{"date":275,"type":47},"2024-04-01",{"date":277,"type":21},"2025-05-31",{"name":279,"class":54},"University Medical Center Goettingen",{"id":281,"slug":282,"hasResults":11,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":286,"eligibilityCriteria":287,"healthyVolunteers":11,"sex":17,"minAge":288,"maxAge":289,"enrollmentInfo":290,"targetDuration":4,"studyType":22,"phases":292,"briefSummary":293,"conditions":294,"keywords":298,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":4},"100550070","phase-4-sglt-2-inhibitor-and-high-dose-furosemide-plus-small-volume-hypertonic-saline-solution-in-acute-hf-100550070","NCT06442280","SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HF","Enhanced Diuresis and Natriuresis in Acute Decompensated Heart Failure Patients Treated With SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution: A Clinical Trial","DAPA-TONIC","Inclusion Criteria:\n\n* acute heart failure;\n* diabetes type 2.\n\nExclusion Criteria:\n\n* low estimated glomerular filtration rate;\n* hypernatremia;\n* diabetes type 1;\n* non-cardiac causes of dyspnea;\n* cardiogenic shock;\n* recent occurrence of Acute Coronary Syndrome;\n* ketoacidosis;\n* hyperosmolar hyperglycemic syndrome.","40 Years","89 Years",{"count":291,"type":21},544,[178],"The purpose of the current investigation is to demonstrate the efficacy of high-dose furosemide plus small-volume hypertonic saline solution and a Sodium-Glucose cotransporter-2 (SGLT-2) inhibitor among patients admitted for acute exacerbation of heart failure, in determining a significant increase in diuresis and natriuresis. It is also accompanied by a rapid reduction in body weight and a substantial decrease in hospitalization length without compromising renal function.",[29,295,296,297],"Diabetes Type 2","Heart Failure With Reduced Ejection Fraction","Heart Failure With Preserved Ejection Fraction",[218,295,299,300,301],"SGLT-2 inhibitors","Furosemide","Hypertonic Solution","2024-06-04",{"date":304,"type":47},"2024-06-06",{"date":306,"type":21},"2024-06",{"date":308,"type":21},"2026-03-30",{"name":310,"class":54},"University of Palermo",{"id":312,"slug":313,"hasResults":11,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":4,"eligibilityCriteria":317,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":318,"targetDuration":320,"studyType":209,"phases":4,"briefSummary":321,"conditions":322,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":55},"100547972","prognostic-model-heart-failure-100547972","NCT06414928","Prognostic Model Heart Failure","In-hospital & 30-day Prognostication of Acute Heart Failure Patients by Comparing 4 Validated Scores in Patients Presenting to the Emergency Department of Cardiac Tertiary Care Hospital, Karachi- Pakistan","Inclusion Criteria:\n\n* Patients of age \\> 18 years or more\n* Either gender\n* Patients visited the emergency department at NICVD, Karachi\n* Newly\u002FAlready diagnosed with Heart Failure\n* Giving informed consent\n* Who can be followed in 30 days via Telephone or in OPD\n\nExclusion Criteria:\n\n* Patients of age \\\u003C18 years\n* Patients who do not give consent\n* Patients who are mentally handicapped due to any neurological or psychiatric illness (excluding depression\u002Fanxiety)",{"count":319,"type":21},1000,"30 Days","This study aims to determine the prognosis of heart failure in our population by using multiple validated risk scores and to evaluate the strengths of these scores in assessing prognosis with better discrimination.",[29],"2024-05-10",{"date":325,"type":47},"2024-05-16",{"date":327,"type":47},"2024-02-14",{"date":329,"type":21},"2026-06-14",{"name":331,"class":54},"National Institute of Cardiovascular Diseases, Pakistan",{"id":333,"slug":334,"hasResults":11,"nctId":335,"briefTitle":336,"officialTitle":336,"acronym":337,"eligibilityCriteria":338,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":339,"targetDuration":4,"studyType":22,"phases":341,"briefSummary":342,"conditions":343,"keywords":345,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":351,"completionDateStruct":353,"leadSponsor":355,"locationsCount":4},"100537097","acetazolamide-or-metolazone-in-acute-heart-failure-100537097","NCT06273397","Acetazolamide or Metolazone in Acute Heart Failure","ACME-AHF","Inclusion Criteria:\n\n* Acute heart failure: Hospitalization due to symptoms of heart failure, congestion signs documented with a congestion score greater than 1, NT-proBNP above 1000 pg\u002Fml.\n* Randomization within 24 hours of admission.\n\nExclusion Criteria:\n\n* Under 18 years of age.\n* Received more than one dose of intravenous furosemide before randomization.\n* Cause of heart failure: hypertrophic or restrictive cardiomyopathy, or constrictive pericarditis.\n* Acute coronary syndrome or severe acute valvulopathy as the cause of decompensation.\n* Systolic blood pressure \\\u003C 90mmHg before randomization.\n* Requirement for vasopressors, inotropes, or invasive mechanical ventilation. Use of intravenous vasodilators or non-invasive mechanical ventilation is allowed.\n* Glomerular filtration rate \\\u003C 20ml\u002Fmin\u002F1.73m2.\n* Potassium \\\u003C 2.5 mEQ\u002FL or Sodium \\\u003C 125 mEQ\u002FL before randomization.\n* pH \\\u003C 7.2 or Bicarbonate \\\u003C 15mEQ\u002FL before randomization.\n* Use of another diuretic in addition to furosemide before randomization. Dapagliflozin or Empagliflozin can be maintained upon admission or initiated early during hospitalization if desired by the treating physician (variable to be recorded).\n* Patients who cannot achieve adequate recording of variables (e.g., inability to quantify diuresis or weight).\n* Pregnant or lactating individuals. If of childbearing age and there is inconsistency with contraceptive use or reasonable doubts about current pregnancy, a pregnancy test must be conducted before study entry.",{"count":340,"type":21},1050,[24],"Impact of Acute Heart Failure:\n\nAccording to the World Health Organization (WHO), approximately 26 million people suffer from Heart Failure (HF), with a mortality rate of up to 50% within five years of diagnosis. Acute Heart Failure (AHF) exacerbations, leading to hospitalization, are common and represent the primary cause of hospital admissions in those over 65. Effective decongestion during hospitalization is crucial, as failure to achieve it doubles the risk of rehospitalization and mortality, incurring significant healthcare costs.\n\nUse of Diuretics in Acute Heart Failure:\n\nDiuretics, particularly loop diuretics like furosemide, are a cornerstone in managing AHF by inducing natriuresis and achieving decongestion. Clinical experience supports their use, though limited clinical trials exist. Pharmacological concepts guide their administration, emphasizing intravenous delivery in high doses and adjusting subsequent doses based on decongestive efficacy. Additionally, sequential tubular blockade with other diuretics like metolazone and acetazolamide is explored to enhance decongestion.\n\nUse of Metolazone and Acetazolamide:\n\nSequential tubular blockade, using metolazone and acetazolamide in conjunction with furosemide, aims to achieve rapid and effective decongestion. While metolazone targets the distal tubule, inhibiting sodium-chloride channels, acetazolamide affects proximal tubular function. Studies like ADVOR (acetazolamide) and CLOROTIC (thiazide-like diuretic) demonstrate the potential benefits of combining these diuretics for quicker decongestion but with potential risks (in the case of Hydrochlorothiazide).\n\nOutcomes Measured by Major Studies:\n\nRecent studies assessing decongestion in AHF reveal a lack of uniformity in outcome selection. The primary focus should be on reducing rehospitalizations and post-discharge mortality by achieving effective decongestion. The ADVOR study, using a simple congestion score based on clinical and imaging criteria, underscores the importance of reaching a congestion score of 0 or 1 promptly.\n\nCongestion Monitoring:\n\nMonitoring diuretic treatment solely based on clinical aspects may not capture subclinical congestion, necessitating biochemical and imaging parameters. The ACME-AHF trial proposes a diagnostic score integrating clinical and imaging aspects to evaluate congestion status. Secondary outcomes include cumulative diuresis, weight loss, diuretic efficiency, and natriuresis, with a focus on natriuresis as a reliable physiological parameter for decongestion.\n\nAim of the study:\n\nThe ACME-AHF trial is designed to compare the efficacy and safety of two diuretic combination strategies: acetazolamide with furosemide and metolazone with furosemide. The primary objective is to relieve congestion, assessed using a congestion score, within the first three days of treatment during an hospitalization for acute heart failure.",[29,344],"Decompensated Heart Failure",[346,347,29],"Acetazolamide","Metolazone","2024-03-14",{"date":350,"type":47},"2024-03-18",{"date":352,"type":21},"2024-05-01",{"date":354,"type":21},"2027-05-01",{"name":356,"class":54},"Clinica Alemana de Santiago",{"id":358,"slug":359,"hasResults":11,"nctId":360,"briefTitle":361,"officialTitle":361,"acronym":362,"eligibilityCriteria":363,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":364,"targetDuration":366,"studyType":209,"phases":4,"briefSummary":367,"conditions":368,"keywords":369,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":374,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":380,"locationsCount":55},"100496645","lesser-poland-cracovian-heart-failure-registry-100496645","NCT05746923","Lesser Poland Cracovian Heart Failure Registry","LECRA-HF","Inclusion Criteria:\n\n* hospitalization due to acute heart failure\n* \\> 18 years of age\n\nExclusion Criteria:\n\n* inability to give informed consent to participate in the registry",{"count":365,"type":21},2500,"5 Years","The goal of Lesser Poland Cracovian Heart Failure Registry (LECRA-HF) is to expand the knowledge about acute heart failure (AHF) and its long-term prognosis.\n\nThe main questions are:\n\n* assessment of long-term prognosis of AHF and its determinants\n* determination of the optimal AHF treatment methods\n* assessment of indications for invasive coronary arteries diagnostics and revascularization and their long-term effects\n* analysis of the particular HF subtypes (HFimpEF, HFpEF, HFsnEF, HFrEF, HFmrEF)",[181,29],[100,71,370,371,372],"decompensation","revascularization","long-term prognosis","2024-03-04",{"date":375,"type":47},"2024-03-06",{"date":377,"type":47},"2023-02-15",{"date":379,"type":21},"2026-12-31",{"name":381,"class":54},"Jagiellonian University",{"id":383,"slug":384,"hasResults":11,"nctId":385,"briefTitle":386,"officialTitle":387,"acronym":4,"eligibilityCriteria":388,"healthyVolunteers":11,"sex":17,"minAge":121,"maxAge":4,"enrollmentInfo":389,"targetDuration":4,"studyType":22,"phases":391,"briefSummary":393,"conditions":394,"keywords":396,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":399,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":405,"locationsCount":55},"100527031","phase-3-sglt2-inhibitors-in-patients-with-adhf-during-ventilator-weaning-100527031","NCT06142474","SGLT2 Inhibitors in Patients With ADHF During Ventilator Weaning","The Potential Beneficial Effects of SGLT2 Inhibitors in Patients With Acute Decompensated Heart Failure During Ventilator Weaning: a Prospective Multicenter Cohort Study.","Inclusion Criteria:\n\n1. Patients aged ≥20 years\n2. Currently hospitalized for the primary diagnosis of acute HF (de novo or decompensated chronic HF) in HFrEF patients (LVEF≤40%)\n3. Meet the stabilization criteria:\n\n   A. Systolic BP ≥100mm Hg and no symptoms of hypotension in the preceding 6 hours B. No increase in i.v. diuretic dose for 6 hours prior to randomization C. No i.v. vasodilators including nitrates within the last 6 hours prior to randomization D. No i.v. inotropic drugs for 24 hours prior to randomization\n4. Elevated N-terminal proB-type natriuretic peptide (NT-proBNP) or BNP:\n\n   A. Without atrial fibrillation (AF): NT-proBNP ≥1600 pg\u002FmL or BNP ≥400 pg\u002FmL B. With AF: NT-proBNP ≥2400 pg\u002FmL or BNP ≥600 pg\u002FmL\n5. Patients were intubated for at least 24 hour with ventilator settings allowing to initiate the weaning process \\[SpO2 \\> 90% or PaO2\u002FFiO2 ≥ 150 mmHg with a fraction of inspired oxygen (FiO2) ≤ 40% and a positive end-expiratory pressure (PEEP) ≤ 8 cmH2O\\].\n\nExclusion Criteria:\n\n1. Decision to withdraw life support\n2. Cardiogenic shock\n3. Hospitalization for HF (HHF) triggered by acute myocardial infarction (AMI) or pulmonary embolism\n4. Planned or previous (within 30 days) cardiovascular revascularization or major cardiac surgery\u002Fintervention\u002Fdevice implantation\n5. Prior acute coronary syndrome, AMI, stroke or transient ischemic accident within 90 days\n6. Estimated glomerular filtration rate (eGFR) of less than 30 ml per minute per 1.73 m2 of body-surface area\n7. Type 1 diabetes mellitus\n8. Poorly controlled type 2 diabetes mellitus (a glycated hemoglobin level above 10.5%)\n9. Uncontrolled urinary tract infection",{"count":390,"type":21},450,[392],"PHASE3","This study will explore the potential benefits of sodium-glucose cotransporter 2 (SGLT2) inhibitors in preventing cardiac ischemia and cardiopulmonary edema in patients with acute decompensated heart failure during weaning from ventilators.",[29,395],"Ventilator Lung",[29,397],"Ventilator","2023-11-16",{"date":400,"type":47},"2023-11-21",{"date":402,"type":47},"2022-10-10",{"date":404,"type":21},"2030-10-09",{"name":406,"class":54},"National Taiwan University Hospital"]